FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3187991575> ?p ?o ?g. }

• W3187991575 endingPage "843" @default.
• W3187991575 startingPage "836" @default.
• W3187991575 abstract "The aim of this study was to evaluate the prognostic impact of FLT3-ITD in core-binding factor acute myeloid leukemia (CBFAML) in an international, multicenter survey of 97 patients of whom 52% had t(8;21)(q22;q22) and 48% had inv(16)(p13q22)/t(16;16)(p13;q22). The median age of the patients was 53 years (range, 19-81). Complete remission after anthracycline-based induction (n=86) and non-intensive therapy (n=11) was achieved in 97% and 36% of the patients, respectively. The median follow-up was 4.43 years (95% confidence interval [95% CI]: 3.35-7.39 years). The median survival after intensive and non-intensive treatment was not reached and 0.96 years, respectively. Among intensively treated patients, inv(16) with trisomy 22 (n=11) was associated with a favorable 4-year relapse-free survival rate of 80% (95% CI: 59-100%) as compared to 38% (95% CI: 27-54%; P=0.02) in all other patients with CBFAML/ FLT3-ITD (n=75). Overall, 24 patients underwent allogeneic hematopoietic cell transplantation (HCT), 12 in first complete remission and 12 after relapse. Allogeneic HCT in first complete remission was not beneficial (P=0.60); however, allogeneic HCT seemed to improve median survival in relapsed patients compared to that of patients treated with chemotherapy (not reached vs. 0.6 years, respectively; P=0.002). Excluding patients with inv(16) with trisomy 22, our data indicate that compathe outcome of CBF-AML patients with FLT3-ITD may be inferior to that of patients without FLT3-ITD (based on previously published data), suggesting that prognostically CBF-AML patients with FLT3-ITD should not be classified as favorable-risk. FLT3-inhibitors may improve the outcome of these patients." @default.
• W3187991575 created "2021-08-16" @default.
• W3187991575 creator A5003682435 @default.
• W3187991575 creator A5006122560 @default.
• W3187991575 creator A5007449495 @default.
• W3187991575 creator A5009387581 @default.
• W3187991575 creator A5011721730 @default.
• W3187991575 creator A5011914281 @default.
• W3187991575 creator A5018576827 @default.
• W3187991575 creator A5023296232 @default.
• W3187991575 creator A5023876572 @default.
• W3187991575 creator A5026359397 @default.
• W3187991575 creator A5027526161 @default.
• W3187991575 creator A5036778361 @default.
• W3187991575 creator A5036912140 @default.
• W3187991575 creator A5037460404 @default.
• W3187991575 creator A5047829491 @default.
• W3187991575 creator A5053949970 @default.
• W3187991575 creator A5055245281 @default.
• W3187991575 creator A5064374340 @default.
• W3187991575 creator A5067065015 @default.
• W3187991575 creator A5067574718 @default.
• W3187991575 creator A5071023119 @default.
• W3187991575 creator A5079124367 @default.
• W3187991575 creator A5086171925 @default.
• W3187991575 creator A5089694123 @default.
• W3187991575 date "2021-08-05" @default.
• W3187991575 modified "2023-10-18" @default.
• W3187991575 title "Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study" @default.
• W3187991575 cites W1967330415 @default.
• W3187991575 cites W1969545468 @default.
• W3187991575 cites W1971056717 @default.
• W3187991575 cites W1971211622 @default.
• W3187991575 cites W2001656423 @default.
• W3187991575 cites W2003664440 @default.
• W3187991575 cites W2011654752 @default.
• W3187991575 cites W2015507761 @default.
• W3187991575 cites W2016231313 @default.
• W3187991575 cites W2022686977 @default.
• W3187991575 cites W2033109201 @default.
• W3187991575 cites W2065464763 @default.
• W3187991575 cites W2073140442 @default.
• W3187991575 cites W2074425311 @default.
• W3187991575 cites W2090318710 @default.
• W3187991575 cites W2090526771 @default.
• W3187991575 cites W2093588238 @default.
• W3187991575 cites W2094912768 @default.
• W3187991575 cites W2096756851 @default.
• W3187991575 cites W2100663913 @default.
• W3187991575 cites W2103513114 @default.
• W3187991575 cites W2110608811 @default.
• W3187991575 cites W2113367077 @default.
• W3187991575 cites W2114242622 @default.
• W3187991575 cites W2117198005 @default.
• W3187991575 cites W2118270328 @default.
• W3187991575 cites W2125929535 @default.
• W3187991575 cites W2132912591 @default.
• W3187991575 cites W2146862320 @default.
• W3187991575 cites W2150113701 @default.
• W3187991575 cites W2158872718 @default.
• W3187991575 cites W2159507916 @default.
• W3187991575 cites W2344085448 @default.
• W3187991575 cites W2546297708 @default.
• W3187991575 cites W2559537906 @default.
• W3187991575 cites W2715749014 @default.
• W3187991575 cites W2725930552 @default.
• W3187991575 cites W2792029111 @default.
• W3187991575 cites W2802281739 @default.
• W3187991575 cites W2886748809 @default.
• W3187991575 cites W2997965570 @default.
• W3187991575 cites W3147894994 @default.
• W3187991575 cites W4293241248 @default.
• W3187991575 cites W4376595466 @default.
• W3187991575 doi "https://doi.org/10.3324/haematol.2021.278645" @default.
• W3187991575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34348451" @default.
• W3187991575 hasPublicationYear "2021" @default.
• W3187991575 type Work @default.
• W3187991575 sameAs 3187991575 @default.
• W3187991575 citedByCount "11" @default.
• W3187991575 countsByYear W31879915752021 @default.
• W3187991575 countsByYear W31879915752022 @default.
• W3187991575 countsByYear W31879915752023 @default.
• W3187991575 crossrefType "journal-article" @default.
• W3187991575 hasAuthorship W3187991575A5003682435 @default.
• W3187991575 hasAuthorship W3187991575A5006122560 @default.
• W3187991575 hasAuthorship W3187991575A5007449495 @default.
• W3187991575 hasAuthorship W3187991575A5009387581 @default.
• W3187991575 hasAuthorship W3187991575A5011721730 @default.
• W3187991575 hasAuthorship W3187991575A5011914281 @default.
• W3187991575 hasAuthorship W3187991575A5018576827 @default.
• W3187991575 hasAuthorship W3187991575A5023296232 @default.
• W3187991575 hasAuthorship W3187991575A5023876572 @default.
• W3187991575 hasAuthorship W3187991575A5026359397 @default.
• W3187991575 hasAuthorship W3187991575A5027526161 @default.
• W3187991575 hasAuthorship W3187991575A5036778361 @default.
• W3187991575 hasAuthorship W3187991575A5036912140 @default.
• W3187991575 hasAuthorship W3187991575A5037460404 @default.
• W3187991575 hasAuthorship W3187991575A5047829491 @default.

• next